Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT05977751
Recruiting Not applicable

Prospective Multi-Center Trial for FemBloc Permanent Birth Control

NCT05977751 · tracked via the Priya Life Science USA tracker
Sponsor
Femasys Inc
Phase
Not applicable
Started
2023-10-31
Last updated
2026-10-23

Condition(s) studied

Contraception

Investigational drug(s) / intervention(s)

FemBloc

FemBloc: Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.

Study summary

Prospective, multi-center, international, unblinded, single-arm trial of subjects undergoing FemBloc followed by ultrasound confirmation test.

Eligibility

Sex
FEMALE
Min age
21 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female, 21 - 50 years of age desiring permanent birth control. * Sexually active with male partner. * Regular menstrual cycle for last 3 months or on hormonal contraceptives. Exclusion Criteria: * Uncertainty about the desire to end fertility. * Known or suspected pregnancy. * Prior tubal surgery, including sterilization attempt. * Presence, suspicion, or previous history of gynecologic malignancy. * Scheduled to undergo concomitant intrauterine procedures (i.e. endometrial ablation) at the time of either FemBloc Treatment or prior to final confirmation test. * Abnormal uterine bleeding requiring evaluation or treatment.

Primary outcome measure(s)

  • Pregnancy Rate — one (1) year
    Number of subjects who were told to rely on FemBloc for birth control and became pregnant through one (1) year.

Trial sites (12)

FacilityCityRegionStatus
New Horizons Clinical Trials Chandler Arizona Recruiting
Stanford University Palo Alto California Recruiting
University of California Davis Sacramento California Recruiting
Midtown OB GYN North Columbus Georgia Recruiting
Atrium Health Navicent Macon Georgia Recruiting
Rosemark WomenCare Specialists Idaho Falls Idaho Recruiting
Maimonides Medical Center Brooklyn New York Recruiting
Columbia University Medical Center/NYPH New York New York Recruiting
Seven Hills Women's Health Centers Cincinnati Ohio Recruiting
Chattanooga Medical Research LLC Chattanooga Tennessee Recruiting
Baylor Scott & White Research Institute Temple Texas Recruiting
University of Utah Salt Lake City Utah Recruiting

More Femasys Inc. trials in the USA

FemBloc® Permanent Contraception - Confirmation Feasibility Trial Active, not recruiting

Other trials for the same condition

Contraceptive Efficacy Study of Ovaprene Recruiting
FemBloc® Permanent Contraception - Confirmation Feasibility Trial Active, not recruiting
Validation of Effectiveness on NaturalCycles Users Recruiting
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05977751 on ClinicalTrials.gov ↗ ← All trials in the USA